

Press release

Contact:

Torben Jörgensen, President and CEO

Tel: +46 707 49 05 84, torben.jorgensen@biotage.com

Biotage AB

Kungsgatan 76

SE-753 18 Uppsala

Tel+46 18 56 59 00

www.biotage.com

Uppsala October 19, 2009

Biotage AB Nomination Committee

A Nomination Committee consisting of shareholder representatives and the Chairman of the Board of Directors has been formed for Biotage AB. The Nomination Committee shall, before the Annual General Meeting 2010, prepare proposals for the election of Chairman and other members of the Board of Directors, the election of Chairman of the Annual General Meeting, the determination of fees and matters pertaining thereto.

The members of the Nomination Committee are:

Björn Odlander, HealthCap

Karl Swartling, Investor Growth Capital

Anders Walldow, Brohuvudet AB and direct holding

Ove Mattsson, Chairman of the Board

Shareholders wishing to submit a proposal for members of the Board of Directors may do so sending e-mail to the Chairman of the Board of Directors of Biotage AB at info@eu.biotage.com.

This is information that Biotage AB (publ) is required to disclose pursuant to the Swedish Securities Markets Act. The information was provided for public release on 19 October 2009 at 12.00 CET

About Biotage

Biotage offers solutions, knowledge and experience in the areas of analytical and medicinal chemistry. The customers include the world's top pharma and biotech companies, as well as leading academic institutes. The company is headquartered in Uppsala, Sweden, and has offices in the United States, United Kingdom and Japan. Biotage has 270 employees and had sales of SEK 385,3m in 2008. Biotage is listed on the NASDAQ OMX Nordic Stock Exchange. Website: www.biotage.com